Medallion Wealth Advisors’s Pacific Biosciences PACB Stock Holding History

Medallion Wealth Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$168	Hold	100	–	–	﹤0.01%	1090
2026 Q1	$132	Hold	100	–	–	﹤0.01%	1107
2025 Q4	$187	Hold	100	–	–	﹤0.01%	1097
2025 Q3	$128	Hold	100	–	–	﹤0.01%	1087
2025 Q2	$129	Hold	100	–	–	﹤0.01%	1076
2025 Q1	$113	Hold	100	–	–	﹤0.01%	1054
2024 Q4	$183	Buy	+100	New	+$195	﹤0.01%	987

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Medallion Wealth Advisors's PACB Position: Q2 2026 in Review

Medallion Wealth Advisors held its Pacific Biosciences (PACB) position steady in Q2 2026 at 100 shares worth $168. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

Medallion Wealth Advisors first reported a position in PACB in Q4 2024 and has held it in 7 quarters since. The position peaked at $187 in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Medallion Wealth Advisors held 100 shares of Pacific Biosciences worth $168 as of Q2 2026.
Medallion Wealth Advisors left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #1090 holding.
Medallion Wealth Advisors first reported a position in Pacific Biosciences in Q4 2024 and has held it in 7 quarters since.
Medallion Wealth Advisors's Pacific Biosciences position peaked at $187 in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.